Nektar Therapeutics (NKTR) CEO Howard W. Robin Sells 83,333 Shares
Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $24.20, for a total value of $2,016,658.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Nektar Therapeutics (NASDAQ NKTR) traded down 2.60% during trading on Tuesday, hitting $23.27. The stock had a trading volume of 1,152,536 shares. The firm’s market cap is $3.64 billion. Nektar Therapeutics has a one year low of $11.41 and a one year high of $25.02. The firm’s 50-day moving average is $21.82 and its 200-day moving average is $20.40.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). The business had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.36) earnings per share. Equities research analysts forecast that Nektar Therapeutics will post ($0.98) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/10/nektar-therapeutics-nktr-ceo-howard-w-robin-sells-83333-shares.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its holdings in Nektar Therapeutics by 180,432.9% during the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock worth $470,234,000 after purchasing an additional 20,024,448 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Nektar Therapeutics during the second quarter worth approximately $34,661,000. PointState Capital LP raised its holdings in Nektar Therapeutics by 281.7% during the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after purchasing an additional 1,277,500 shares in the last quarter. Vanguard Group Inc. raised its holdings in Nektar Therapeutics by 4.9% during the first quarter. Vanguard Group Inc. now owns 13,607,980 shares of the biopharmaceutical company’s stock worth $319,379,000 after purchasing an additional 634,700 shares in the last quarter. Finally, FMR LLC raised its holdings in Nektar Therapeutics by 42.4% during the first quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock worth $45,711,000 after purchasing an additional 580,341 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.
A number of analysts have weighed in on NKTR shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research report on Friday, August 18th. BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, August 1st. Roth Capital set a $33.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, HC Wainwright started coverage on Nektar Therapeutics in a research report on Monday, August 7th. They set a “buy” rating and a $31.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $26.80.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.